1. Home
  2. PLG vs SLN Comparison

PLG vs SLN Comparison

Compare PLG & SLN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Platinum Group Metals Ltd. (Canada)

PLG

Platinum Group Metals Ltd. (Canada)

HOLD

Current Price

$1.58

Market Cap

223.4M

Sector

N/A

ML Signal

HOLD

Logo Silence Therapeutics Plc American Depository Share

SLN

Silence Therapeutics Plc American Depository Share

HOLD

Current Price

$6.20

Market Cap

236.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
PLG
SLN
Founded
2000
1994
Country
Canada
United Kingdom
Employees
N/A
116
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
223.4M
236.2M
IPO Year
2002
N/A

Fundamental Metrics

Financial Performance
Metric
PLG
SLN
Price
$1.58
$6.20
Analyst Decision
Buy
Analyst Count
0
5
Target Price
N/A
$42.60
AVG Volume (30 Days)
2.2M
255.6K
Earning Date
04-10-2026
03-05-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.99
$1.97
52 Week High
$4.04
$7.91

Technical Indicators

Market Signals
Indicator
PLG
SLN
Relative Strength Index (RSI) 26.27 52.83
Support Level $1.39 $5.79
Resistance Level $1.69 $7.40
Average True Range (ATR) 0.15 0.69
MACD -0.07 -0.00
Stochastic Oscillator 3.16 42.71

Price Performance

Historical Comparison
PLG
SLN

About PLG Platinum Group Metals Ltd. (Canada)

Platinum Group Metals Ltd is a development-stage company, conducts work on mineral properties it has staked or acquired by way of option agreements in the Republic of South Africa. Key metals of economic interest on the company's mineral properties include platinum, palladium, rhodium, gold, copper, and nickel. The company operates in one segment, the development of the Waterberg Project in South Africa, and geographically in Canada and South Africa.

About SLN Silence Therapeutics Plc American Depository Share

Silence Therapeutics PLC is a biotechnology company focused on discovering and developing novel molecules incorporating short-interfering ribonucleic acid or siRNA. Using its mRNAi GOLD platform, the company has generated siRNA product candidates both for internal development pipeline as well as for out-licensed programs with third-party collaborators. Its wholly owned pipeline is focused on three therapeutic areas: cardiovascular disease, hematology, and rare diseases. The different product candidates in its pipeline are Divesiran (SLN124), a siRNA product candidate that has the potential to treat several hematological disorders; Zerlasiran (SLN360), being developed as a potential treatment to reduce cardiovascular issues; SLN-312; SLN-548; and multiple other programs.

Share on Social Networks: